Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03328026
Title Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors BriaCell Therapeutics Corporation

breast cancer


Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM

Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.